Ginipral - a drug that reduces the contractile activity and muscle tone of the uterus.
Release form and composition
Make tablets Ginipral containing the active substance - hexoprenaline sulfate - 500 µg, as well as excipients: lactose hydrate, corn starch, disodium edetate dihydrate, copovidone, magnesium stearate, glycerol palmitate stearate, talc. In blisters of 10 pieces.
Make Ginipral solution for intravenous administration, containing in 1 ampoule 10 μg of hexoprenaline sulfate, as well as additional substances: water for injection, sodium chloride, sodium pyrosulfite, disodium edetate dihydrate, sulfuric acid 2N. In ampoules of 2 ml, 5 pieces in a box.
Make Ginipral concentrate for solution for infusion, containing in 1 ml of 25 μg of hexoprenaline sulfate, as well as auxiliary components: deionized water, sodium chloride, sodium pyrosulfate, sulfuric acid, disodium edetate dihydrate. In packs of 5 ampoules.
Indications for use
According to the instructions, Ginipral solution and concentrate for the preparation of the solution are shown for use in the following cases:
- Acute tocolysis: slowing of labor contractions during childbirth due to acute intrauterine asphyxia, umbilical cord prolapse, before turning the fetus from a transverse position, before a caesarean section, complication of labor activity;
- Premature delivery (as an emergency measure before the patient is taken to hospital);
- Massive tocolysis: the suspension of premature birth in the presence of a smoothed cervix and disclosure of the uterine cavity;
- Prolonged tocolysis: increased and intensified contractions without disclosure of the uterus and smoothing of the cervix (for the prevention of preterm labor), immobilization of the uterus before, during and after cervical cerclage;
Ginipral tablets prescribed for the threat of preterm birth (mainly as a continuation of infusion treatment).
According to the instructions, Ginipral should not be taken in the following cases:
- Coronary heart disease;
- Aortic stenosis, mitral valve disease;
- Premature detachment of the placenta, uterine bleeding;
- First trimester of pregnancy;
- Severe renal and / or liver dysfunction;
- High blood pressure;
- Angle-closure glaucoma;
- Breastfeeding period;
- Intrauterine infections;
- Hypersensitivity to the active or auxiliary components of the drug.
Dosing and Administration
The dose of Ginpral solution is selected individually. The contents of the ampoule should be administered slowly intravenously for 5-10 minutes - after dilution with isotonic NaCl solution.
In acute tocolysis, 1 ampoule (2 ml) is prescribed. If necessary, treatment is continued using infusions;
In case of massive tocolysis, treatment with a solution is prescribed in the amount of 1 ampoule with subsequent infusion of Ginipral at a rate of 0.3 μg per minute.
With prolonged tocolysis, the drug is prescribed as a continuous drip infusion at a rate of 0.075 μg per minute.
If the resumption of contractions does not occur within two days, the patient is transferred to taking Ginipral tablets.
Concentrate for preparing a solution of Guinipral should be diluted before use in 5 ml of distilled water so that the total concentration of the active substance is 5 μg in 1 ml of solution.
The finished solution is used parenterally, in the form of intravenous injections and infusions. The dosage of parenteral administration of Ginipral is determined individually, depending on the clinical symptoms.
Ginipral tablets are taken orally with a sufficient amount of liquid.
With the threat of preterm labor, 1 tablet of Ginipral is prescribed 1-2 hours before the end of the infusion.
The medicine is taken 1 tablet every three hours, then 1 tablet every 4-6 hours. The daily dose of Ginipral should not exceed 4-8 tablets.
The use of Ginipral may cause the following side effects:
- Cardiovascular system: lowering blood pressure, maternal tachycardia, cardiac rhythm disturbances, cardialgia;
- Central and peripheral nervous systems: anxiety, dizziness, tremor of the fingers, headache;
- The digestive system: intestinal obstruction, nausea and vomiting, deterioration of intestinal motility, a temporary increase in hepatic transaminases;
- Laboratory indicators: hypocalcemia, hypokalemia, increased plasma glucose levels;
- Allergies: bronchospasm, difficulty breathing, impaired consciousness, anaphylactic shock;
- Side effects of Ginipral in newborns: acidosis, hypoglycemia.
During treatment with Ginipral, patients should monitor the function of the cardiovascular system of the mother and fetus.
In case of hypersensitivity to sympathomimetics, it is recommended that Ginipral be prescribed at low doses and under constant medical supervision.
If the mother has a pronounced increase in heart rate (more than 130 beats per minute) or a significant decrease in blood pressure, the dose of Ginipral should be reduced.
In the event of signs of heart failure, pain in the area of the heart, shortness of breath, the use of Ginipral should be immediately stopped.
In women with diabetes mellitus, carbohydrate metabolism indices should be monitored during Ginipral therapy, since the use of the medication may cause an increase in plasma glucose levels.
In some cases, the simultaneous use of Ginipral and glucocorticosteroids can cause pulmonary edema, especially in cases of renal dysfunction. Therefore, the patient during treatment should be under regular medical supervision.
The structural analogues of Ginipral are Ipradol and Hexoprenaline.
Drugs that have similar pharmacological effects are: Partusisten, Salbutamol, Fenoterol, Magnesia.
Terms and conditions of storage
According to the instructions, Ginipral stored in a dark, dry, out of reach of children. The shelf life of the solution and concentrate is 3 years, tablets - 5 years.